• N Y Pshenichnaya, E N Kareva, I A Leneva, V A Bulgakova, I E Kravchenko, I V Nikolaeva, A I Grekova, A P Ivanova, L V Puzyreva, G M Khasanova, S N Orlova, E P Tikhonova, V A Petrov, O V Malinin, N V Kolaeva, E V Volchkova, N N Kanshina, and V P Chulanov.
• National Medical Research Center of Tuberculosis and Infectious Diseases.
• Terapevt Arkh. 2021 Nov 15; 93 (11): 1306-1315.

AimAn analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness.Materials And MethodsThe study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001).ResultsDuring hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics.ConclusionUmifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.

29 keywords...

hide…